Federal health advisers say AstraZeneca's Onglyza and a related diabetes drug should carry new information about a possible association with heart failure and death.
Apr 14, 2015
Individuals with type 2 diabetes, who are resistant to insulin, have an excess blood glucose level, which they are now trying to reduce using a new class of diabetes drugs known as the gliflozins. These new ...
4 hours ago